Market opportunity for H&N cancer

Market opportunity for H&N cancer

The global head and neck cancer incidence is 625,000 new patients per year (Menezes et al., 2021)[1]. Approximately 70% of these patients qualify for radiotherapy (Pignon 2009).

The global market for head and neck cancer is expected to reach $4.5 billion by 2027, growing at CAGR 17.3% over the forecast period, driven by rising epidemic of oropharyngeal cancer associated with HPV, and anticipated approval of checkpoint inhibitors. (iHealthcareAnalyst, 2020)

[1] Santos Menezes, F. dos Santos; Fernandes, G.A.; Ferreira Antunes, J.L.; Lina Villa, L.; Toporcov, T.N.; Global incidence trends in head and neck cancer for HPV-related and -unrelated subsites: A systematic review of population-based studies, Oral Oncology, Volume 115, 2021. doi: 10.1016/j.oraloncology.2020.105177